Source:http://linkedlifedata.com/resource/pubmed/id/16803861
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2006-9-26
|
pubmed:abstractText |
The endogenous mu-opioid receptor agonist, endomorphin (EM)-1, cannot be delivered into the central nervous system (CNS) in sufficient quantity to elicit analgesia when given systemically because it is severely restricted by the blood-brain barrier (BBB). To improve the physicochemical characteristics of EM-1 and subsequently achieve greater BBB permeation, we synthesized a series of EM-1 analogs by combining successful chemical modifications, including N-terminal cationization, C-terminal chloro-halogenation, and unnatural amino acid (d-Ala, Sar, and d-Pro-Gly) substitutions in position 2. Presently, their binding and bioassay activity, lipophilicity, stability, and antinociceptive activity were determined and compared. Guanidino-addition and chloro-halogenation attenuated the mu-receptor affinity to some extent, but they demonstrated differences in the influence on stability. It appeared that guanidino-addition contributed to brain stability enhancement for the greater part, whereas chloro-halogenation together with amino acid substitutions in position 2 was of more importance for the stability enhancement in serum than in brain. Determination of the octanol/buffer coefficient revealed that chloro-halogenation did compromise the decreased lipophilicity caused by guanidino-addition, and introduction of d-Ala as well as d-Pro-Gly, but not Sar, in place of l-Pro(2), also increased the overall lipophilicity to some extent. Among the peptides tested, intracerebroventricular injection of guanidino-[d-Ala(2), p-Cl-Phe(4)]EM-1 showed the strongest analgesia, being 3 times more potent than the parent peptide. We also found that in comparison with EM-1, the four d-Ala-containing tetrapeptides and the chloro-halogenated d-Pro-Gly-containing pentapeptide elicited significant and prolonged central-mediated analgesia upon subcutaneous administration, indicating that more peptides reached the CNS, eliciting greater analgesic effect.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0022-3565
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
319
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
308-16
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16803861-Analgesics, Opioid,
pubmed-meshheading:16803861-Animals,
pubmed-meshheading:16803861-Blood-Brain Barrier,
pubmed-meshheading:16803861-Drug Stability,
pubmed-meshheading:16803861-Female,
pubmed-meshheading:16803861-Guinea Pigs,
pubmed-meshheading:16803861-Male,
pubmed-meshheading:16803861-Mice,
pubmed-meshheading:16803861-Oligopeptides,
pubmed-meshheading:16803861-Permeability,
pubmed-meshheading:16803861-Radioligand Assay,
pubmed-meshheading:16803861-Rats,
pubmed-meshheading:16803861-Solubility,
pubmed-meshheading:16803861-Structure-Activity Relationship
|
pubmed:year |
2006
|
pubmed:articleTitle |
Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1.
|
pubmed:affiliation |
Department of Biochemistry and Molecular Biology, School of Life Sciences, Lanzhou University, 222 Tianshui South Road, Lanzhou 730000, People's Republic of China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|